545 related articles for article (PubMed ID: 25762619)
1. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
5. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.
Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S
Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629
[TBL] [Abstract][Full Text] [Related]
7. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
8. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
9. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
10. Hydrogen peroxide impairs insulin-stimulated assembly of mTORC1.
Zhang L; Kimball SR; Jefferson LS; Shenberger JS
Free Radic Biol Med; 2009 Jun; 46(11):1500-9. PubMed ID: 19281842
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes.
Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A
Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151
[TBL] [Abstract][Full Text] [Related]
12. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation dynamics of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) is discordant with its potential to interact with eukaryotic initiation factor 4E (eIF4E).
Showkat M; Beigh MA; Bhat BB; Batool A; Andrabi KI
Cell Signal; 2014 Oct; 26(10):2117-21. PubMed ID: 24975846
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
15. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
16. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
[TBL] [Abstract][Full Text] [Related]
17. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
18. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
19. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Liu L; Chen L; Chung J; Huang S
Oncogene; 2008 Aug; 27(37):4998-5010. PubMed ID: 18504440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]